Gland Pharma Shares Hit 52-Week High As Q2 Net Profit Jumps

Gland Pharma shares jumped over 6.73 percent to hit a new 52-week high in Monday's trading session, defying a broader sell-off across the Indian stock market. The stock opened at 3,147 rupees per share on the National Stock Exchange, compared to its previous close of 3,132.80 rupees on Sunday, and later touched an intraday high of 3,352 rupees on November 9.

Financial Results

The strong stock performance follows the company's financial results reported on Friday, November 6. Drugmaker Gland Pharma posted a 58.2 percent year-on-year jump in net profit, reaching 291 crore rupees for the second quarter of the 2027 financial year, up from 184 crore rupees in the same period last year. Revenue rose 23.3 percent to 1,834 crore rupees, while earnings before interest, tax, depreciation, and amortization surged 54.1 percent to 484 crore rupees. The company's research and development spending stood at 107.7 crore rupees, making up 6 percent of consolidated revenue.

Market Context

Meanwhile, benchmark Indian indices Sensex and Nifty opened lower on Monday due to selling pressure in heavy IT stocks and profit-booking after a recent market rally. The BSE Sensex fell 93.95 points to 80,919.19, and the NSE Nifty 50 declined 30 points to 24,968.80. Despite the broader market dip, Gland Pharma shares have surged 93.87 percent year-to-date and 78.48 percent over the past year, though its five-year performance remains negative with an 8.26 percent decline.

Context

Stock prices often move independently of broader market trends when individual companies report strong earnings or profit growth that beats expectations. Pharmaceutical firms regularly invest a portion of their revenue into research and development to build a pipeline of complex products for future growth.